> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Petition Seeks Risk-Based Peptide Framework
- URL: https://www.fdaweb.com/petition-seeks-risk-based-peptide-framework/
- Published: 2026-01-07T12:00:00.000Z
- Updated: 2026-09-14T15:30:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160447

A petition submitted to FDA by **Sarfaraz Niazi**, described online as an academic biopharmaceutical expert, calls on the agency to adopt a formal guidance or incorporate into an existing guidance a risk-based regulatory framework for peptide therapeutics. The [petition](https://downloads.regulations.gov/FDA-2025-P-7433-0001/attachment%5F2.pdf?ref=fdaweb.com) also calls on FDA to:

- clarify that approval of an oral peptide therapeutic does not constitute a platform precedent for oral peptide delivery; and
- apply the framework prospectively to discourage scientifically unjustified development programs for dose-sensitive peptides that rely on highly variable delivery routes.

The petition says FDA’s multiple guidances relevant to various aspects of peptide development were not designed to address the unique intersection of dose sensitivity and exposure variability that characterizes peptide therapeutics.

“Adoption of the proposed guideline would improve patient safety, enhance regulatory predictability, reduce wasted development efforts, and align regulatory decisions with pharmacological reality,” the petition concludes.